EcoDrugPlus

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSSDUG00000012242
Gene Symbol: HTR1A
2 Cross references
104 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a-Beta

Ensembl ID : ENSSDUG00000002158
Gene Symbol: LOC111221198
3 Cross references
132 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSSDUG00000011090
Gene Symbol: HTR1B
2 Cross references
184 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSSDUG00000017921
Gene Symbol: HTR1B
4 Cross references
183 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSSDUG00000001578
Gene Symbol: HTR1E
4 Cross references
148 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSSDUG00000013721
Gene Symbol: HTR1F
4 Cross references
142 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSSDUG00000012739
Gene Symbol: HTR2A
3 Cross references
213 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSSDUG00000005202
Gene Symbol: HTR2B
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSSDUG00000014409
Gene Symbol: LOC111233466
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSSDUG00000021988
Gene Symbol: HTR3A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSSDUG00000006394
Gene Symbol: HTR4
3 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSSDUG00000006689
Gene Symbol: HTR5A
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).